StocksMedium•14 November 2026•
1 min read
EMA Committee Upholds Regulatory Rejection of Cessatech's KemSu Treatment
Key Facts
1The EMA's CHMP upheld its negative opinion regarding the marketing authorization for Cessatech's pediatric pain treatment, KemSu.
The European Medicines Agency's CHMP upheld its negative opinion regarding the marketing authorization for Cessatech's pediatric pain treatment, KemSu. Benzinga reported that the committee maintained its previous stance following a re-evaluation of the application, effectively blocking the treatment's path to the European market.
The ruling serves as a significant regulatory setback for Cessatech, preventing the commercialization of a key product within the European Union. This development follows recent regional data from November 13, 2026, which showed EU annual employment growth at 0.4% and a trade balance deficit of 10.3 billion euros.